These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9211626)

  • 1. Topical application of low molecular weight heparin in a rabbit traumatic anastomosis model.
    Fu K; Izquierdo R; Vandevender D; Warpeha RL; Wolf H; Fareed J
    Thromb Res; 1997 Jun; 86(5):355-61. PubMed ID: 9211626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis model.
    Fu K; Izquierdo R; Walenga JM; Fareed J
    Thromb Res; 1995 Jun; 78(5):421-8. PubMed ID: 7660358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
    Hiebert LM
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin exerts an early antithrombotic effect in small arteries and veins following severe trauma.
    Zhang B; Wieslander JB
    Microsurgery; 1992; 13(6):295-8. PubMed ID: 1333564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved microsurgical anastomotic patency with low molecular weight heparin.
    Ritter EF; Cronan JC; Rudner AM; Serafin D; Klitzman B
    J Reconstr Microsurg; 1998 Jul; 14(5):331-6. PubMed ID: 9714039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of microvascular thrombosis by topical application of recombinant tissue factor pathway inhibitor.
    Lantieri LA; Ozbek MR; Deune EG; Ornberg RL; Brown DM; Chung SH; Wun TC; Cooley BC; Khouri RK
    Plast Reconstr Surg; 1996 Mar; 97(3):587-94. PubMed ID: 8596790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma.
    Khouri RK; Koudsi B; Kaiding F; Ornberg RL; Wun TC
    Ann Plast Surg; 1993 May; 30(5):398-402; discussion 402-4. PubMed ID: 8342923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the early antithrombotic effects between low molecular weight heparin and heparin in small arteries following a severe trauma: an experimental study.
    Zhang B; Dougan P; Wieslander JB
    Ann Plast Surg; 1993 Sep; 31(3):255-61. PubMed ID: 8239417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
    Zhang B; Wieslander JB
    Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis.
    Durand E; Helley D; Al Haj Zen A; Dujols C; Bruneval P; Colliec-Jouault S; Fischer AM; Lafont A
    J Vasc Res; 2008; 45(6):529-37. PubMed ID: 18463418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate of crushed arterial anastomoses.
    Korompilias AV; Chen LE; Seaber AV; Urbaniak JR
    J Hand Surg Am; 1997 May; 22(3):540-6. PubMed ID: 9195468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of enoxaparin, standard heparin, and streptokinase on the patency of anastomoses in severely crushed arteries.
    Chen LE; Seaber AV; Korompilias AV; Urbaniak JR
    Microsurgery; 1995; 16(10):661-5. PubMed ID: 8676728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-adjusted strategies in the prevention of early arterial thrombosis following lower extremity arterial reconstruction: a comparison of unfractionated versus low molecular weight heparin.
    Winkler MS; Larena-Avellaneda A; Diener H; Kölbel T; Debus ES
    J Cardiovasc Surg (Torino); 2013 Feb; 54(1 Suppl 1):183-92. PubMed ID: 23443603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated doses of oral and subcutaneous heparins have similar antithrombotic effects in a rat carotid arterial model of thrombosis.
    Hiebert LM; Ping T; Wice SM
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):110-6. PubMed ID: 21512111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.